Amir Zeki

Prof. Amir Zeki


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
TCTara F. Carr
Tara F. Carr
AZAmir Zeki
Amir Zeki
MKMonica Kraft
Monica Kraft
Asthma can be subdivided into eosinophilic or non-eosinophilic phenotypes based on the inflammatory cellular patterns seen in sputum, blood, and airway tissue compartments. However, this level of stratification does not always produce robust clinical phenotypes as there is considerable overlap across these phenotypes when viewed from the perspective of “eosinophilia”. Multiple proposed subphenotypes of asthma have instead been described within both the eosinophilic and non-eosinophilic groups. An endotype is the mechanism driving a subphenotype including those associated with eosinophilia such as early-onset allergic asthma, with and without obesity, aspirin sensitive asthma and late-onset eosinophilic asthma, allergic bronchopulmonary mycosis, and exercise-induced asthma. Conversely, subphenotypes of asthma not associated with eosinophilia include those of obesity-induced asthma, asthma with fixed airflow obstruction and minimal inflammation (paucigranulocytic), neutrophilic asthma, and asthma associated with smoking, pollution, infection, or other respiratory irritants. Each of these subphenotypes may have one or more endotype or mechanism driving their clinical presentation. We review the known mechanisms that define each endotype and that lead to the clinical presentation of the known eosinophilic and non-eosinophilic subphenotypes. This approach yields important information regarding potential preventative or therapeutic interventions in these patients with asthma.

3 September 2015 in Allergy
Verified
Journal Article
Open access
PDF file
AZAmir Zeki
Amir Zeki
BYB. Yeganeh
B. Yeganeh
NKN. J. Kenyon
N. J. Kenyon
MPM. Post
M. Post
Saeid GhavamiSaeid Ghavami
Saeid Ghavami
The study of autophagy (‘self‐eating’), a fundamental cell fate pathway involved in physiological and pathological subcellular processes, opens a new frontier in the continuous search for novel therapies for human asthma. Asthma is a complex syndrome with different disease phenotypes. Autophagy plays a central role in cell physiology, energy and metabolism, and cell survival. Autophagy's hallmark is the formation of double‐membrane autophagic autophagosomes, and this process is operational in airway epithelial and mesenchymal cells in asthma. Genetic associations between autophagy genes and asthma have been observed including single nucleotide polymorphisms in Atg5 which correlate with reduced lung function. Immune mechanisms important in asthma such as Th2 cells and eosinophils also manifest autophagy. Lastly, we address the role of autophagy in extracellular matrix deposition and fibrosis in asthmatic airways remodeling, a pathologic process still without effective therapy, and discuss potential pharmacologic inhibitors. We end by offering two opposing but plausible hypotheses as to how autophagy may be directly involved in airway fibrosis.

30 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
PSPawan Sharma
Pawan Sharma
JAJavad Alizadeh
Javad Alizadeh
MJMaya Juarez
Maya Juarez
Afshin SamaliAfshin Samali
Afshin Samali
AHAndrew Halayko
Andrew Halayko
AZAmir Zeki
Amir Zeki
Autophagy, apoptosis, and the unfolded protein response (UPR) are fundamental biological processes essential for manifold cellular functions in health and disease. Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal pulmonary disorder associated with aging that has limited therapies, reflecting our incomplete understanding. We conducted an observational study linking molecular markers of cell stress response pathways (UPR: BiP, XBP1; apoptosis: cleaved caspase-3; autophagy: LC3β) in lung tissues from IPF patients and correlated the expression of these protein markers to each subject’s lung function measures. We hypothesized that changes in lung tissue expression of apoptosis, autophagy, and UPR markers correlate with lung function deficits in IPF. The cell stress markers BiP, XBP1, LC3β puncta, and cleaved caspase-3 were found to be elevated in IPF lungs compared to non-IPF lungs, and, further, BiP and cleaved caspase-3 co-localized in IPF lungs. Considering lung function independently, we observed that increased XBP1, BiP, and cleaved caspase-3 were each associated with reduced lung function (FEV1, FVC, TLC, RV). However, increased lung tissue expression of LC3β puncta was significantly associated with increased diffusion capacity (DLCO), an indicator of alveolar–capillary membrane function. Similarly, the co-localization of UPR (XBP1, BiP) and autophagy (LC3β puncta) markers was positively correlated with increased lung function (FEV1, FVC, TLC, DLCO). However, the presence of LC3β puncta can indicate either autophagy flux inhibition or activation. While the nature of our observational cross-sectional study design does not allow conclusions regarding causal links between increased expression of these cell stress markers, lung fibrosis, and lung function decline, it does provide some insights that are hypothesis-generating and suggests that within the milieu of active UPR, changes in autophagy flux may play an important role in determining lung function. Further research is necessary to investigate the mechanisms linking UPR and autophagy in IPF and how an imbalance in these cell stress pathways can lead to progressive fibrosis and loss of lung function. We conclude by presenting five testable hypotheses that build on the research presented here. Such an understanding could eventually lead to the development of much-needed therapies for IPF.

22 December 2020 in Life
Verified
Journal Article
Open access
PDF file
MAMahmoud Aghaei
Mahmoud Aghaei
SDSanaz Dastghaib
Sanaz Dastghaib
SASajjad Aftabi
Sajjad Aftabi
Mohamad-Reza AghanooriMohamad-Reza Aghanoori
Mohamad-Reza Aghanoori
JAJavad Alizadeh
Javad Alizadeh
Saeid GhavamiSaeid Ghavami
Saeid Ghavami
Cellular protein homeostasis in the lungs is constantly disrupted by recurrent exposure to various external and internal stressors, which may cause considerable protein secretion pressure on the endoplasmic reticulum (ER), resulting in the survival and differentiation of these cell types to meet the increased functional demands. Cells are able to induce a highly conserved adaptive mechanism, known as the unfolded protein response (UPR), to manage such stresses. UPR dysregulation and ER stress are involved in numerous human illnesses, such as metabolic syndrome, fibrotic diseases, and neurodegeneration, and cancer. Therefore, effective and specific compounds targeting the UPR pathway are being considered as potential therapies. This review focuses on the impact of both external and internal stressors on the ER in idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) and discusses the role of the UPR signaling pathway activation in the control of cellular damage and specifically highlights the potential involvement of non-coding RNAs in COPD. Summaries of pathogenic mechanisms associated with the ER stress/UPR axis contributing to IPF and COPD, and promising pharmacological intervention strategies, are also presented.

1 January 2021 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
SDSanaz Dastghaib
Sanaz Dastghaib
PKP. Sravan Kumar
P. Sravan Kumar
SASajjad Aftabi
Sajjad Aftabi
GDGautam Damera
Gautam Damera
ADAzadeh Dalvand
Azadeh Dalvand
AZAmir Zeki
Amir Zeki
Lung cells are constantly exposed to various internal and external stressors that disrupt protein homeostasis. To cope with these stimuli, cells evoke a highly conserved adaptive mechanism called the unfolded protein response (UPR). UPR stressors can impose greater protein secretory demands on the endoplasmic reticulum (ER), resulting in the development, differentiation, and survival of these cell types to meet these increasing functional needs. Dysregulation of the UPR leads to the development of the disease. The UPR and ER stress are involved in several human conditions, such as chronic inflammation, neurodegeneration, metabolic syndrome, and cancer. Furthermore, potent and specific compounds that target the UPR pathway are under development as future therapies. The focus of this review is to thoroughly describe the effects of both internal and external stressors on the ER in asthma. Furthermore, we discuss how the UPR signaling pathway is activated in the lungs to overcome cellular damage. We also present an overview of the pathogenic mechanisms, with a brief focus on potential strategies for pharmacological interventions.

Verified
Journal Article
Open access
PDF file
ASAmir Seyfoori
Amir Seyfoori
MBMahdieh Shokrollahi Barough
Mahdieh Shokrollahi Barough
PMpooneh mokarram
pooneh mokarram
MAMazaher Ahmadi
Mazaher Ahmadi
Parvaneh MehrbodParvaneh Mehrbod
Parvaneh Mehrbod
Mohsen AkbariMohsen Akbari
Mohsen Akbari
Viral-associated respiratory infectious diseases are one of the most prominent subsets of respiratory failures, known as viral respiratory infections (VRI). VRIs are proceeded by an infection caused by viruses infecting the respiratory system. For the past 100 years, viral associated respiratory epidemics have been the most common cause of infectious disease worldwide. Due to several drawbacks of the current anti-viral treatments, such as drug resistance generation and non-targeting of viral proteins, the development of novel nanotherapeutic or nano-vaccine strategies can be considered essential. Due to their specific physical and biological properties, nanoparticles hold promising opportunities for both anti-viral treatments and vaccines against viral infections. Besides the specific physiological properties of the respiratory system, there is a significant demand for utilizing nano-designs in the production of vaccines or antiviral agents for airway-localized administration. SARS-CoV-2, as an immediate example of respiratory viruses, is an enveloped, positive-sense, single-stranded RNA virus belonging to the coronaviridae family. COVID-19 can lead to acute respiratory distress syndrome, similarly to other members of the coronaviridae. Hence, reviewing the current and past emerging nanotechnology-based medications on similar respiratory viral diseases can identify pathways towards generating novel SARS-CoV-2 nanotherapeutics and/or nano-vaccines.